eNewsroom for: Gem Pharmaceuticals

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Gem Pharmaceuticals/Screen-Shot-2014-03-18-at-5.06.46-PM.png

Gem Pharmaceuticals Company Profile

Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. In so doing, Gem seeks to transform traditional broad-spectrum cytotoxic drugs into modern – and biochemically targeted – anti-cancer agents that hold the potential for higher dosing and correspondingly improved therapeutic utility. Gem believes that its lead non-cardiotoxic anthracycline compound (GPX-150) has the potential to attain significant market penetration by replacing the existing use of doxorubicin and other anthracyclines; by expanding the oncology uses of anthracyclines; and by broadening anthracycline use beyond cancer.

News from Gem Pharmaceuticals:

Gem Pharmaceuticals Presents Promising Phase 2 Data for GPX-150 in Sarcoma Patients at the 2016 ASCO Annual Meeting

Clear evidence of pharmacologic activity and an attractive safety profile BIRMINGHAM, Ala., June 7, 2016 /PRNewswire/ — Gem Pharmaceuticals announced preliminary Phase 2 results of its lead drug candidate, GPX-150, in sarcoma patients this week at the annual meeting of the American Societ…

Gem Pharmaceuticals Receives U.S. Orphan Drug Designation for GPX-150 in the Treatment of Patients With Sarcoma

Phase 2 clinical trial results projected for late 2016 BIRMINGHAM, Ala., Jan. 6, 2016 /PRNewswire/ — Gem Pharmaceuticals announced today that the U.S. Food and Drug Administration has granted orphan drug designation to GPX-150, the Company's lead product candidate that is currently u…

Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients

BIRMINGHAM, Ala., Jan. 23, 2015 /PRNewswire/ — Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial.  This open-label study will assess the efficacy and safety of Gem's lead compound…

Gem Pharmaceuticals Announces $4.5 Million Financing

New Investment Will Fund the Company's Upcoming Phase 2 Clinical Trial in Sarcoma Patients BIRMINGHAM, Ala., March 19, 2014 /PRNewswire/ — Gem Pharmaceuticals announced today that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 milli…